Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 25, 2026

4 Consumer Favorites Look Oversold Right Now: Disney, McDonald’s and More

View original at finance.yahoo.com
4 Consumer Favorites Look Oversold Right Now: Disney, McDonald’s and More Quick Read McDonald’s (MCD) trades at $309 with RSI at 29.88 after a sharp pullback, yet Q4 FY2025 U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 54 of 57 analysts rate Microsoft stock at Buy or Strong Buy, with a consensus target of $591.60

    60% confidence
  • Price action reflects macro anxiety around AI capex spending rather than any deterioration in the business

    60% confidence
  • Analyst consensus target for P&G is $168.00, and model sees $159.69, or 11.1% upside

    60% confidence
  • 54 of 57 analysts rate Microsoft stock at Buy or Strong Buy with consensus target of $591.60

    60% confidence
  • Microsoft predicted price at $498.23, implying 32.2% upside from current levels, with bull case of $601.71

    60% confidence
  • Price action reflects macro anxiety around AI capex spending rather than deterioration in Microsoft's business

    60% confidence
  • Model puts Microsoft predicted price at $498.23, implying 32.2% upside from current levels, with a bull case of $601.71

    60% confidence
  • Macro fear is outpacing economic reality as retail sales remain near 12-month highs while consumer sentiment sits at 55.5

    60% confidence
  • Consumer sentiment weakness is driving sharp selloffs despite strong underlying business performance and resilient retail spending

    60% confidence
  • Plans around $10 billion in dividends and $5 billion in buybacks for FY2026

    60% confidence
  • Consumer sentiment weakness is driving sharp selloffs despite strong underlying business performance and resilient retail spending

    60% confidence
  • Procter & Gamble analyst consensus target is $168.00 with model showing $159.69, or 11.1% upside

    60% confidence

Data points we hold from this source

The Walt Disney Company · rsi29.74 index
The Walt Disney Company · streaming operating income450 USD
The Walt Disney Company · experiences revenue10.006 USD
The Walt Disney Company · streaming operating income growth72 percent
The Walt Disney Company · streaming operating income growth72 percent
McDonald's Corporation · rsi29.88 index
McDonald's Corporation · comparable sales growth6.8 percent
McDonald's Corporation · active users210 millions
McDonald's Corporation · loyalty program sales37 USD
Procter & Gamble · predicted price159.69 USD
Procter & Gamble · 52 week low137.62 USD
Procter & Gamble · 1 month return-12.7 percent
Procter & Gamble · one month return-12.7 percent
Procter & Gamble · analyst consensus target168.00 USD
Procter & Gamble · one year return-12.5 percent
Procter & Gamble · rsi29.6 index
Procter & Gamble · 1 year return-12.5 percent
Procter & Gamble · planned buybacks5 USD
Procter & Gamble · planned dividends10 USD
Procter & Gamble · tariff headwind400 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com